Zacks1d agobullish
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock UpHALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
News
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
312last 24h
1803last 7d
320🟢 bullish (7d)
187🔴 bearish (7d)
129publishers